Plain-English translation of NCT07243561 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a nasal spray called hUC-MSC-EXOs that contains tiny particles derived from human umbilical cord stem cells. Researchers want to see if spraying this treatment into the nose every other day can safely help improve core symptoms of autism in children ages 3 to 7. The study will compare children who receive the medication to children who receive no treatment, and both groups will be carefully monitored for 24 weeks.
Autism spectrum disorder affects how children communicate and interact with others, and many children don't improve enough with behavioral therapy alone. This medication is being tested because early research suggests that stem cell particles may help reduce autism symptoms and improve a child's ability to communicate and interact with others.
You likely qualify if…
You likely don't qualify if…
If your child is assigned to receive the medication, you will give them the nasal spray every other day for a total of 10 doses over 24 weeks. If your child is assigned to the control group, they will receive no treatment but will still come to all the same visits and health checks. Both groups will have regular appointments where your child will be assessed for changes in autism symptoms and checked for any side effects.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China